0001193125-16-649390.txt : 20160715 0001193125-16-649390.hdr.sgml : 20160715 20160715161002 ACCESSION NUMBER: 0001193125-16-649390 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160715 DATE AS OF CHANGE: 20160715 EFFECTIVENESS DATE: 20160715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLOBEIMMUNE INC CENTRAL INDEX KEY: 0001245104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841353925 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35642 FILM NUMBER: 161769769 BUSINESS ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 BUSINESS PHONE: 3036252744 MAIL ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 25 1 d144888d25.htm 25 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-35642

 

 

GlobeImmune, Inc.

The NASDAQ Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

 

 

1450 Infinite Drive

Louisville, CO 80027

Telephone: (303) 625-2700

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices))

Common Stock, par value $0.001 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

¨ 17 CFR 240.12d2-2(a)(1)

 

¨ 17 CFR 240.12d2-2(a)(2)

 

¨ 17 CFR 240.12d2-2(a)(3)

 

¨ 17 CFR 240.12d2-2(a)(4)

 

¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

 

x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, GlobeImmune, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

July 15, 2016   By:      /s/ Timothy C. Rodell       Chief Executive Officer and President
Date        Name       Title